SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

[X]    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934.

       For the quarterly period ended June 30, 2001.

       OR

[ ]    TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934.

       For the transition period from              to
                                      ------------    ------------

       Commission file number  ---  0-16335

                          Bio-Medical Automation, Inc.
                          ----------------------------
       (Exact name of small business issuer as specified in its charter.)

                Colorado                                       84-0922701
      ----------------------------                         -------------------
      (State or other jurisdiction                            (IRS Employer
            of incorporation)                              Identification No.)


            10 South Street, Suite 202, Ridgefield, Connecticut 06877
            ---------------------------------------------------------
               (Address of Principal Executive Office) (Zip Code)

                                 (203) 894-9755
                                 --------------
                (Issuer's telephone number, including area code)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes  X   No
                                                              ---     ---

As of August 10, 2001 the Registrant had outstanding 795,528 shares of common
stock, par value $.10.

Transitional Small Business Disclosure Format (check one):
Yes              No  X
    ---             ---

<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                                   FORM 10-QSB
                                 MARCH 31, 2001




                                Table of Contents
                                -----------------



Part I.     Financial Information                                           Page

     Item 1.     Financial Statements

                 Balance Sheets as of June 30, 2001 and
                      December 31, 2000 (unaudited)                            3

                 Statements of Operations for the Six
                      Months Ended June 30, 2001 and
                      2000 and Cumulative Amounts from
                           January 1, 2000 through June 30, 2001 (unaudited)   4

                 Statements of Operations for the Three Months Ended
                      June 30, 2001 and 2000 (unaudited)                       5

                 Statements of Cash Flows for the Six
                      Months Ended June 30, 2001 and
                      2000 and Cumulative Amounts from
                           January 1, 2000 through June 30, 2001 (unaudited)   6

                 Notes to Financial Statements                                 7

     Item 2.     Management's Plan of Operation                                8

Part II.

     Item 6.     Exhibits and Reports on Form 8-K                             10

     Signatures                                                               10



                                        2
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                   June 30,      December 31,
                                                                               2001 (Unaudited)      2000
<S>                                                                              <C>             <C>
CURRENT ASSETS
    Cash                                                                         $   346,223     $   360,741
                                                                                 -----------     -----------

        Total Current Assets                                                         346,223         360,741
                                                                                 -----------     -----------

OTHER ASSETS
    Note receivable - related                                                         50,000              --
    Interest receivable- related                                                         756              --
                                                                                 -----------     -----------

                                                                                      50,756              --
                                                                                 -----------     -----------


                                                                                 $   396,979     $   360,741
                                                                                 ===========     ===========


                                 LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable and accrued expenses                                        $     6,238     $     3,599
                                                                                 -----------     -----------

        Total Current Liabilities                                                      6,238           3,599
                                                                                 -----------     -----------


STOCKHOLDERS' EQUITY
    Preferred Stock, $.10 par value; authorized - 1,000,000 shares
       Issued - none
    Common Stock, $.10 par value; authorized - 5,000,000 shares
       Issued and outstanding - 795,528 (2001) and 707,128 shares (2000)              79,553          70,713
    Capital in excess of par value                                                 1,442,809       1,353,649
    Stock issued for deferred compensation                                           (35,000)        (11,000)
    Accumulated (deficit)                                                           (947,820)       (947,820)
    (Deficit) accumulated during the development stage                              (148,801)       (108,400)
                                                                                 -----------     -----------

                                                                                     390,741         357,142
                                                                                 -----------     -----------

                                                                                 $   396,979     $   360,741
                                                                                 ===========     ===========
</TABLE>

                See accompanying notes to financial statements.

                                        3
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

                                                              Cumulative
                                                             Amounts from
                                       Six Months Ended    January 01, 2000
                                            June 30,              to
                                      2001          2000     June 30, 2001

REVENUES
      Interest income              $   4,234     $   2,855     $   9,793
                                   ---------     ---------     ---------

OPERATING EXPENSES
    General and Administrative        44,635        51,137       139,870
      Write-off of patent                 --        18,724        18,724
                                   ---------     ---------     ---------

                                      44,635        69,861       158,594
                                   ---------     ---------     ---------


NET (LOSS)                         $ (40,401)    $ (67,006)    $(148,801)
                                   =========     =========     =========

NET (LOSS) PER COMMON SHARE
    Basic and Diluted
                                   $   (0.05)    $   (0.10)    $    (.21)
                                   =========     =========     =========



WEIGHTED AVERAGE NUMBER OF
    COMMON SHARES OUTSTANDING -
    Basic and Diluted                752,801       661,795       707,639
                                   =========     =========     =========




                See accompanying notes to financial statements.

                                        4
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

                                           Three Months Ended
                                                June 30,
                                           2001          2000

REVENUES
          Interest Income               $   2,484     $      --
                                        ---------     ---------

OPERATING EXPENSES
          General and Administrative       20,605        17,100
          Write-off of patent                  --        18,724
                                        ---------     ---------

                                           20,605        35,824
                                        ---------     ---------

NET (LOSS)                              $ (18,121)    $ (35,824)
                                        =========     =========

NET (LOSS) PER COMMON SHARE
          Basic and Diluted
                                        $   (0.02)    $   (0.05)
                                        =========     =========


WEIGHTED AVERAGE NUMBER OF COMMON
          SHARES OUTSTANDING
          Basic and Diluted               795,528       680,461
                                        =========     =========





                 See accompanying notes to financial statements

                                        5
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                      Cumulative
                                                                Six Months Ended     Amounts from
                                                                    June 30,      January 01, 2000 to
                                                               2001          2000    June 30, 2001
<S>                                                        <C>           <C>           <C>
CASH FLOWS FROM OPERATING ACTIVITES
         Net (loss)                                        $ (40,401)    $ (67,006)    $(148,801)
         Adjustment to reconcile net (loss) to net cash
            (used) by operating activities
            Stock issuance for salary                         24,000        13,000        61,000
            Write-off of patent                                   --        18,724        18,724
         Changes in assets and liabilities
            (Increase) in interest receivable                   (756)           --          (756)
            (Decrease) increase in accounts payable and
                  accrued expenses                             2,639        (7,987)       (9,156)
                                                           ---------     ---------     ---------

        Net Cash (Used) by Operating Activities              (14,518)      (43,269)      (78,989)
                                                           ---------     ---------     ---------

CASH FLOWS FROM INVESTING ACTIVITIES

        Net Cash (Used) in Investing Activities                   --            --            --
                                                           ---------     ---------     ---------

CASH FLOWS FROM FINANCING ACTIVITIES


        Net Cash (Used) by Financing Activities                   --            --            --
                                                           ---------     ---------     ---------

NET (DECREASE) IN CASH                                       (14,518)      (43,269)      (78,989)

CASH, BEGINNING OF PERIODS                                   360,741       425,212       425,212
                                                           ---------     ---------     ---------

CASH, END OF PERIODS                                       $ 346,223     $ 381,943     $ 346,223
                                                           =========     =========     =========
</TABLE>


                 See accompanying notes to financial statements.

                                        6
<PAGE>

         The unaudited financial statements included herein were prepared from
the records of the Company in accordance with Generally Accepted Accounting
Principles and reflect all adjustments which are, in the opinion of management,
necessary to provide a fair statement of the results of operations and financial
position for the interim periods. Such financial statements generally conform to
the presentation reflected in the Company's Form 10-KSB filed with the
Securities and Exchange Commission for the year ended December 31, 2000. The
current interim period reported herein should be read in conjunction with the
Company's Form 10-KSB subject to independent audit at the end of the year.

         The results of operations for the six months ended June 30, 2001 are
not necessarily indicative of the results that may be expected for the year
ending December 31, 2001.


NOTE 1. COMMON STOCK

In March 2001, the Company issued 38,400 shares of common stock (valued at $
1.25 per share) to its President for services to be rendered to the Company for
the period of March 25, 2001 through March 24, 2002. Compensation expense to the
Company is recorded as the shares are earned. Unearned shares are shown in the
accompanying financial statement as stock issued for deferred compensation.
Additionally, the company loaned the president $50,000 at 6.0%, due March 30,
2003 to exercise warrants to purchase 50,000 shares of the Company's common
stock.






                                        7
<PAGE>

Item 2.  Management's Plan of Operation

     The following discussion and analysis provides information which the
Company's management believes to be relevant to an assessment and understanding
of the Company's results of operations and financial condition. This discussion
should be read together with the Company's financial statements and the notes to
financial statements, which are included in this report, as well as the
information contained in the Company's Form 10-KSB for the year ended December
31, 2000, which is incorporated herein by reference.

Disclosure Regarding Forward Looking Statements
-----------------------------------------------

     Except for historical information contained herein, the statements in this
report are forward-looking statements that are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You can
identify these forward-looking statements when you see words such as "expect,"
"anticipate," "estimate," "may," "believe," and other similar expressions. These
statements are not guarantees of future performance and are subject to certain
risks, uncertainties and assumptions that are difficult to predict. Actual
results could differ materially from those projected in the forward-looking
statements. Forward-looking statements involve known and unknown risks and
uncertainties, which may cause the Company's actual results in future periods to
differ materially, from forecasted results. These and other risks are described
elsewhere herein and in the Company's other filings with the Securities and
Exchange Commission, namely the Company's Form 10-KSB for the year ended
December 31, 2000.

     Bio-Medical Automation, Inc. was incorporated as a Colorado corporation on
October 13, 1983 under the name OZO Diversified Automation, Inc. On March 9,
1999, the Company completed the sale of substantially all of its assets to JOT
Automation, Inc. (the "JOT Transaction"). In connection with the JOT Transaction
the Company changed its name to Bio-Medical Automation, Inc. ("BMA" or the
"Company").

     Following the JOT Transaction the Company devoted its efforts to the
development of a prototype micro-robotic device (the "micro-robotic device") to
manipulate organic tissues on an extremely small scale. Due to the inability to
complete the micro-robotic device, the Company has determined that it will no
longer pursue the sale or development of its micro-robotic device and, as of
June 30, 2000, the capitalized costs related to the patent underlying the
micro-robotic have been written off by the Company. The Company has never
derived any revenues from the micro-robotic device and the Company does not
expect that it will ever derive any revenues from this technology.

     Currently, the Company has suspended all operations, except for necessary
administrative matters relating to the timely filing of periodic reports as
required by the Securities Exchange Act of 1934. Accordingly, during the six
months ended June 30, 2001 and the year ended December 31, 2000, the Company has
earned no revenues from operations.

     The Company's plan of operation is to seek to arrange for a merger,
acquisition, business combination or other arrangement by and between the
Company and a viable operating entity. The Company has not identified a viable
operating entity for a merger, acquisition, business combination or other
arrangement, and there can be no assurance that the Company will ever
successfully arrange for a merger, acquisition, business combination or other
arrangement by and between the Company and a viable operating entity.



                                        8
<PAGE>

     The Company anticipates that the selection of a business opportunity will
be a complex process and will involve a number of risks, because potentially
available business opportunities may occur in many different industries and may
be in various stages of development. Due in part to depressed economic
conditions in a number of geographic areas, rapid technological advances being
made in some industries and shortages of available capital, management believes
that there are numerous companies seeking either the limited additional capital
which the Company will have or the benefits of a publicly traded corporation, or
both. The perceived benefits of a publicly traded corporation may include
facilitating or improving the terms upon which additional equity financing may
be sought, providing liquidity for principle shareholders, creating a means for
providing incentive stock options or similar benefits to key employees,
providing liquidity for all shareholders and other factors.

     In some cases, management of the Company will have the authority to effect
acquisitions without submitting the proposal to the shareholders for their
consideration. In some instances, however, the proposed participation in a
business opportunity may be submitted to the shareholders for their
consideration, either voluntarily by the Board of Directors to seek the
shareholders' advice and consent, or because of a requirement of state law to do
so.

     In seeking to arrange a merger, acquisition, business combination or other
arrangement by and between the Company and a viable operating entity,
management's objective will be to obtain long-term capital appreciation for the
Company's shareholders. However, there can be no assurance that the Company will
be able to complete any merger, acquisition, business combination or other
arrangement by and between the Company and a viable operating entity.

     The Company may need additional funds in order to complete a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there can be no assurance that the Company will be
able to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there can be no assurance that the Company will be able
to complete a merger, acquisition or other arrangement by and between the
Company and a viable operating entity.

Results of Operations
---------------------

     For the three months ended June 30, 2001, the Company has not earned any
revenues, except for interest income of $2,484. For the same period the Company
incurred general and administrative expenses of $20,605 resulting in a net loss
from operations equal to $18,121. General and administrative expenditures have
been directed to maintaining the Company's status as a public company, including
(without limitation) filing reports with the Securities and Exchange Commission
and seeking a merger, acquisition or other arrangement by and between the
Company and a viable operating entity.

Liquidity and Capital Resources
-------------------------------

     During three months ended June 30, 2001, the Company satisfied its working
capital needs from cash on hand at the beginning of the quarter and cash
generated from interest income during the quarter. As of June 30, 2001, the
Company had on hand cash in the amount of $346,223.

     Management believes that the Company's future financial condition will be
subject to its ability to arrange for a merger, acquisition or a business
combination with an operating business on favorable terms that will result in
profitability. There can be no assurance that the Company will be able to do so
or, if it is able to do so, that the transaction will be on favorable terms not
resulting in an unreasonable amount of dilution to the Company's existing
shareholders.

                                        9
<PAGE>

     The Company may need additional funds in order to complete a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that the Company will be able
to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there is no assurance that the Company will be able to
successfully complete a merger, acquisition or other arrangement by and between
the Company and a viable operating entity.


                           PART II - OTHER INFORMATION

Item 6.  Exhibits and Reports on Form 8-K

         a)  Exhibits

             None.

         b)  The Company did not file any current reports on Form 8-K during the
             quarter ended June 30, 2000.


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                 BIO-MEDICAL AUTOMATION, INC.


                                 By: /s/ Steven N. Bronson
                                     ----------------------------------------
                                     Steven N. Bronson, President
                                     (Principle Executive Officer,
                                     as Registrant's duly authorized officer)



Dated:  August 13, 2001




                                       10